Diseases affecting the brain and central nervous system represent one of the largest global healthcare challenges and greatest medical needs due to the devastating personal and economic consequences for patients, caregivers and society.

Despite the fact that an estimated 55 million people worldwide suffer from neurodegenerative diseases, and this incidence is expected to double every 20 years, there are currently no approved disease-modifying therapies or cures available. Leveraging its three integrated platforms, Yumanity Therapeutics’ innovative new approach to drug discovery and development concentrates on reversing the cellular phenotypes and disease pathologies caused by protein misfolding.

LEARN MORE

LATEST NEWS

April 29, 2016

Tony Coles – on a mission to tackle Alzheimer’s

VIEW MORE

April 21, 2016

Tony Coles Fireside Chat | 2016 MassBio Annual Meeting [Video]

VIEW MORE

September 30, 2015

Yumanity Therapeutics Named a 2015 “Fierce 15” Biotech Company

VIEW MORE

ARCHIVE